Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance vs Observation in NDMM
NCT02155634Phase 3Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Jul 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Planned start Jul 2014; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02155634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155634.